Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β–Directed Therapies and Other Labeling Updates

Key Points

• The study aims to explore the implications of FDA approval of amyloid-β PET drugs to enhance patient selection for amyloid-β directed therapies in Alzheimer Disease.
• Evaluation of FDA approval status for amyloid-β PET drugs
• Analysis of theranostic approaches in Alzheimer Disease
• Comparison with oncologic theranostic applications
• FDA approved amyloid-β PET drugs for use in conjunction with therapies
• Emphasis on targeting molecular markers for improved patient outcomes
• Potential changes in clinical guidelines for Alzheimer's therapy based on these approvals